Ride for a Cause: Help Us PHly on World PH Day!
Thanks for visiting the Team PHenomenal Hope and Actelion World PH Day Challenge donation page. As part of Actelion’s continued commitment to the pulmonary arterial hypertension (PAH) community, we are proud to partner with Team PHenomenal Hope for this activity to continue to raise awareness of this serious and progressive disease. We understand that people living with pulmonary arterial hypertension (PAH) often endure a long and difficult journey to diagnosis and ultimately to find an effective treatment to manage their disease. PAH is medically complex, and each treatment decision has the potential to impact disease progression and PAH hospitalizations.
In honor of World PH Day, Actelion and Team PHenomenal Hope are hosting a “Let Me Be Your Lungs” cycling fundraising event on the Actelion South San Francisco campus. If interested, come rally for a great cause by helping Team PHenomonal Hope raise funds for medical research and patient programs. We are honored to partner with this organization for this activity.
Please support our riders! Below is a list of Actelion employees who are at the ready to “PHly” for this cause.
ABOUT PULMONARY ARTERIAL HYPERTENSION (PAH)
Pulmonary arterial hypertension (PAH) is a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs of an affected individual. The symptoms of PAH are non-specific and can range from mild breathlessness and fatigue during normal daily activity to symptoms of right heart failure and severe restrictions on exercise capacity and ultimately reduced life expectancy. PAH is one group within the classification of pulmonary hypertension (PH). This group includes idiopathic PAH, heritable PAH and PAH caused by factors which include connective tissue disease, HIV infection and congenital heart disease.
The last decade has seen significant advances in the understanding of the pathophysiology of PAH, which has been paralleled with developments of treatment guidelines and new therapies. Drugs targeting the three pathways that have been established in the pathogenesis of PAH are endothelin receptor antagonists (ERAs), prostacyclin analogs and phosphodiesterase-5 inhibitors. PAH treatments have transformed the prognosis for PAH patients from symptomatic improvements in exercise tolerance 10 years ago to delayed disease progression today. Improved disease awareness and evidence-based guidelines developed from randomized controlled clinical trial data have highlighted the need for early intervention, goal-oriented treatment and combination therapy.
Actelion, a leader in Pulmonary Arterial Hypertension, became part of the Janssen Pharmaceutical Companies of Johnson & Johnson following its acquisition in June 2017. Actelion's medicines have helped to expand and strengthen Janssen's portfolio with leading, differentiated in-market medicines and promising late-stage compounds. Janssen has added Pulmonary Hypertension as a therapeutic area of focus to maintain the leadership position Actelion has built within this rare disease area. Learn more at www.actelion.com. Follow us at @actelion_com.